RGNX Company Profile and Key Details
REGENXBIO Inc.
RGNX Stock Price Chart
Stock Price Today
REGENXBIO Inc. (RGNX) stock surged +2.25%, trading at $7.74 on NASDAQ, up from the previous close of $7.57. The stock opened at $7.53, fluctuating between $7.34 and $7.77 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Company Information
| Employees | 344 |
| Beta | 1.23 |
| Sales or Revenue | $90.24M |
| 5Y Sales Change% | -0.654% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
REGENXBIO Inc. (NASDAQ: RGNX) stock price is $7.74 in the last trading session. During the trading session, RGNX stock reached the peak price of $7.77 while $7.34 was the lowest point it dropped to. The percentage change in RGNX stock occurred in the recent session was 2.25% while the dollar amount for the price change in RGNX stock was $0.17.
The NASDAQ listed RGNX is part of Biotechnology industry that operates in the broader Healthcare sector. REGENXBIO Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Vittal K. Vasista
Executive Vice President & Chief Financial Officer
Mr. Andrew Yost
Vice President of Corporation Devel.
Mr. Kenneth T. Mills
Pres, Chief Executive Officer & Director
Dr. Olivier Danos Ph.D.
Executive Vice President & Chief Scientific Officer
Dr. Stephen Pakola M.D.
Executive Vice President & Chief Medical Officer
Mr. Patrick J. Christmas II, J.D.
Executive Vice President & Chief Legal Officer
Ms. Shiva G. Fritsch
Chief Communications Officer & Chief People Officer
Dr. Ram Palanki Pharm.D.
Executive Vice President of Commercial Strategy & Operations
Mr. Curran M. Simpson M.S.
Executive Vice President & Chief Operating Officer
Dr. Laura A. Coruzzi J.D., Ph.D.
Executive Vice President of Intellectual Property
Ms. Tricia Truehart
Head of Investor Relations
RGNX's closing price is 15.4% higher than its 52-week low of $6.56 where as its distance from 52-week high of $28.80 is -73.72%.
Number of RGNX employees currently stands at 344.
Official Website of RGNX is: https://www.regenxbio.com
RGNX could be contacted at phone 240 552 8181 and can also be accessed through its website. RGNX operates from 9804 Medical Center Drive, Rockville, MD 20850, United States.
RGNX stock volume for the day was 521.12K shares. The average number of RGNX shares traded daily for last 3 months was 1.28M.
The market value of RGNX currently stands at $383.48M with its latest stock price at $7.74 and 49.55M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com